Dr Reddy's Laboratories Ltd 500124
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan — Update
-
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan
-
Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic
-
Dr. Reddy's on Pace for Largest Percent Increase Since June 2025 — Data Talk
-
Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs — 2nd Update
-
Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs — Update
-
Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs
-
Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 832.99M
- Market Cap
- ₹998.56B
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 32.00
- Price/Sales
- 3.02
- Dividend Yield (Trailing)
- 0.67%
- Dividend Yield (Forward)
- 0.67%
- Dividend Payment Schedule
- Jul
- Total Yield
- 0.67%
Company Profile
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 27,527
- Website
- https://www.drreddys.com
Competitors
Valuation
|
Metric
|
500124
|
TEVA
|
VTRS
|
|---|---|---|---|
Price/Earnings (Normalized) | 32.00 | 16.43 | 6.93 |
Price/Book Value | 2.62 | 5.91 | 1.41 |
Price/Sales | 3.02 | 2.64 | 1.38 |
Price/Cash Flow | 19.31 | 15.20 | 7.11 |
Price/Earnings
500124
TEVA
VTRS
Financial Strength
|
Metric
|
500124
|
TEVA
|
VTRS
|
|---|---|---|---|
Quick Ratio | 1.31 | 0.46 | 0.82 |
Current Ratio | 1.90 | 0.88 | 1.58 |
Interest Coverage | 10.27 | 1.79 | −0.38 |
Quick Ratio
500124
TEVA
VTRS
Profitability
|
Metric
|
500124
|
TEVA
|
VTRS
|
|---|---|---|---|
Return on Assets (Normalized) | 7.17% | 6.68% | 7.94% |
Return on Equity (Normalized) | 10.86% | 35.32% | 19.79% |
Return on Invested Capital (Normalized) | 9.39% | 14.43% | 11.04% |
Return on Assets
500124
TEVA
VTRS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|<CK#@!Vr | LOCK|B$!! | $67B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|L$$^n>k^ | LOCK|nwx#x | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|%@<lNHT | LOCK|<QG | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|&<J@<N% | LOCK|S&J | $29B | |||
| Viatris Inc
VTRS
| LOCK|wvd<@HV | LOCK|KW | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|dG | LOCK|dM | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|$mMlMR | LOCK|N< | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|%LYY#^ | LOCK|FS | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|>KW?L%k | LOCK|c<&j | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|F%<dGTw | LOCK|$P | $2B |
United States